Insmed (INSM) opened Q1 2026 with revenue of US$306 million and a basic EPS loss of US$0.76, while the trailing twelve months show revenue of US$820 million and a basic EPS loss of US$5.70. Over the past reported quarters, revenue has moved from US$93 million in Q1 2025 to US$306 million in Q1 2026, alongside quarterly basic EPS losses ranging between US$0.76 and US$1.75. This keeps the focus squarely on how efficiently new sales translate into narrowing losses. For investors, the story this quarter is less about the top line in isolation and more about how the revenue base interacts with margins and the path toward more sustainable profitability.

See our full analysis for Insmed.

With the headline numbers in place, the next step is to see how this earnings print lines up against the widely followed growth and risk narratives around Insmed, and where those stories might need updating.

Losses Narrow While Net Income Remains Deeply Negative

• Net income for Q1 2026 was a loss of US$163.6 million, compared with losses between US$235.5 million and US$370.0 million in recent quarters, while trailing 12 month net income stands at a loss of about US$1.2b.
• Analysts' consensus narrative that Insmed is investing heavily ahead of anticipated brensocatib launches and possible ARIKAYCE label expansion is tested by the fact that losses over the past five years have grown at about 26.2% per year, even as trailing 12 month revenue of US$819.6 million reflects the build out of a larger commercial base.
  • This pattern supports the idea that spending on R&D and commercial infrastructure is substantial relative to current sales. That aligns with expectations for future product launches rather than current profitability.
  • At the same time, the continued loss of about US$1.2b on a trailing 12 month basis highlights how much operating leverage needs to show up before the consensus view on long term profitability can play out.

Revenue Expands Faster Than Profitability

• Quarterly revenue moved from US$92.8 million in Q1 2025 to US$305.9 million in Q1 2026, while trailing 12 month revenue is US$819.6 million and the company remains unprofitable, with earnings forecast in the supplied data to grow about 63.44% per year and revenue at 33.7% per year.
• The bullish narrative that anticipated U.S. and international brensocatib launches plus potential ARIKAYCE label expansion can support strong long term revenue growth lines up with the 33.7% revenue growth metric. Yet the current trailing 12 month loss of about US$1.2b and EPS loss of US$5.70 show that turning that growth into lasting earnings is still an open execution test.
  • The consensus view that planned launches and Phase II data milestones could open new revenue streams sits against the reality that, so far, higher activity has not yet produced positive margins on a trailing 12 month basis.
  • Forecasts in the input that profitability could arrive within three years rely on future operating leverage that is not visible yet in the recent net income line.

Analysts who want to see how these growth expectations connect to detailed narratives around future products and valuation can go deeper with the full community view See what the community is saying about Insmed.

Valuation Signals Pull In Opposite Directions

• The stock trades on a P/S of 27.6x compared with 9.1x for peers and 10.9x for the U.S. Biotechs industry, yet is described in the data as about 69.1% below a DCF fair value of US$339.26 and also below the single allowed analyst price target of US$211.65, while the current share price is US$104.80.
• Bears focus on the combination of a high P/S multiple, a five year loss growth rate of about 26.2% per year and recent shareholder dilution. The same data set points to strong forecast revenue and earnings growth plus a share price below both the DCF fair value and the allowed analyst target, which gives bulls quantitative support even as the business remains loss making today.
  • The gap between the US$104.80 share price and the US$211.65 analyst target, as well as the DCF fair value at US$339.26, is what bullish investors point to when arguing the stock could have valuation upside if growth and margin assumptions play out.
  • Critics counter that paying 27.6x sales for a company with trailing 12 month losses of about US$1.2b and a history of dilution means those upside scenarios depend heavily on forecasts rather than current profitability.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Insmed on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of growth hopes and ongoing losses feels finely balanced, it may be worth reviewing the underlying data yourself and stress testing both sides of the story. To see how the current bull and bear arguments compare in one place, take a closer look at the 3 key rewards and 1 important warning sign

See What Else Is Out There

Insmed combines a high 27.6x P/S multiple with trailing 12 month losses of about US$1.2b, so profitability risk and valuation uncertainty remain elevated.

If you want stocks where pricing looks more grounded in current fundamentals, it is worth scanning the 51 high quality undervalued stocks right now to compare alternatives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.